Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer
O. Saatci, R. Alam, K.-T. Huynh-Dam, A. Isik, M. Uner, N. Belder, P. G. Ersan, M. Cetin, U. M. Tokat, M. E. Gedik, H. Bal, O. S. Sahin, Y. Riazalhosseini, D. Thieffry, D. Gautheret, , O. Sahin
This study identifies LINC00152 as a driver of tamoxifen resistance in ER+ breast cancer by inhibiting ferroptosis, and shows that targeting LINC00152 restores sensitivity to tamoxifen.
bioRxiv · Nov 5, 2023Cancer Biology